Summit Therapeutics Statistics
Total Valuation
SMMT has a market cap or net worth of $14.99 billion. The enterprise value is $14.58 billion.
Important Dates
The next estimated earnings date is Wednesday, April 30, 2025, before market open.
| Earnings Date | Apr 30, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
SMMT has 737.68 million shares outstanding. The number of shares has increased by 15.96% in one year.
| Current Share Class | 737.68M |
| Shares Outstanding | 737.68M |
| Shares Change (YoY) | +15.96% |
| Shares Change (QoQ) | +1.49% |
| Owned by Insiders (%) | 80.11% |
| Owned by Institutions (%) | 12.62% |
| Float | 115.17M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 38.56 |
| P/TBV Ratio | 38.74 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.15, with a Debt / Equity ratio of 0.02.
| Current Ratio | 10.15 |
| Quick Ratio | 9.89 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -24.29 |
Financial Efficiency
Return on equity (ROE) is -94.90% and return on invested capital (ROIC) is -45.49%.
| Return on Equity (ROE) | -94.90% |
| Return on Assets (ROA) | -41.31% |
| Return on Invested Capital (ROIC) | -45.49% |
| Return on Capital Employed (ROCE) | -53.57% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.39M |
| Employee Count | 159 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +441.87% in the last 52 weeks. The beta is -1.04, so SMMT's price volatility has been lower than the market average.
| Beta (5Y) | -1.04 |
| 52-Week Price Change | +441.87% |
| 50-Day Moving Average | 20.45 |
| 200-Day Moving Average | 17.12 |
| Relative Strength Index (RSI) | 52.17 |
| Average Volume (20 Days) | 2,332,367 |
Short Selling Information
| Short Interest | 21.22M |
| Short Previous Month | 21.63M |
| Short % of Shares Out | 17.83% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 7.34 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -210.99M |
| Pretax Income | -161.69M |
| Net Income | -221.32M |
| EBITDA | -210.90M |
| EBIT | -210.99M |
| Earnings Per Share (EPS) | -$0.31 |
Full Income StatementBalance Sheet
The company has $412.35 million in cash and $7.22 million in debt, giving a net cash position of $405.13 million or $0.55 per share.
| Cash & Cash Equivalents | 412.35M |
| Total Debt | 7.22M |
| Net Cash | 405.13M |
| Net Cash Per Share | $0.55 |
| Equity (Book Value) | 388.75M |
| Book Value Per Share | 0.53 |
| Working Capital | 382.02M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$142.11 million and capital expenditures -$139,000, giving a free cash flow of -$142.25 million.
| Operating Cash Flow | -142.11M |
| Capital Expenditures | -139,000 |
| Free Cash Flow | -142.25M |
| FCF Per Share | -$0.19 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |